Prokinetics influence the pharmacokinetics of rabeprazole

Proton pump inhibitors (PPIs) are unstable at a low PH. Accelerated transfer of PPIs to the upper small intestine may influence the pharmacokinetics of PPIs.

To see if concomitant use of mosapride citrate with rabeprazole sodium influences the pharmacokinetics of the PPI.

Two-way crossover pharmacokinetic studies were conducted in 9 healthy subjects. 20 mg of rabeprazole was given orally and plasma was obtained before and 1, 2, 3, 4, 5, 6 and 8 h after the dosing. Two weeks later, 5 mg of mosapride was given concomitantly with rabeprazole and plasma was collected as above. The plasma concentrations of rabeprazole were determined by high-performance liquid chromatography. The maximum plasma concentrations (C(max)) and the area under the time-plasma concentration curve (AUC) of rabeprazole, and the time to maximum plasma concentration (t(max)) were compared in the presence or absence of mosapride.

Concomitant use of mosapride resulted in significant increases of mean C(max) and mean AUC with ratios of 1.57 and 1.47, respectively. The median t(max) changed from 4 to 3 h, although the change was not significant.

Mosapride significantly influenced pharmacokinetics of rabeprazole. Co-administration of mosapride could have some favorable effect in PPIs-based therapy.